Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Nathan Connell on Conversion from Eptacog Alfa to Beta
Dec 15, 2025, 12:34

Nathan Connell on Conversion from Eptacog Alfa to Beta

Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:

”New Research: Real-World Evidence on Recombinant Factor VIIa Substitution

I’m excited to share our team’s latest publication in Clinical Applied Thrombosis Clinical and Applied Thrombosis/Hemostasis.

We conducted a retrospective evaluation of our conversion from eptacog alfa (NovoSeven) to eptacog beta (Sevenfact) to assess both clinical safety and financial impact at Brigham and Women’s Hospital.

Key Findings:

  • Safety: The transition to eptacog beta showed no adverse thrombotic events across the patient cohort.
  • Efficacy: Effective management was maintained for indications including hemophilia bleeding and peri-procedural management.
  • Impact: The medication use evaluation identified an estimated cost avoidance of $554,400 over 12 months.

This study supports the viability of therapeutic interchange for rFVIIa products, offering a pathway for other institutions to maintain high-quality care while optimizing costs.”

Read the full article here.

Article: Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center

Authors: George AR, Sylvester KW, Kanaan DM, Reddy P, Fanikos JR, Connors JM, Connell NT

Nathan Connell on Conversion from Eptacog Alfa to Beta

Stay updated on all scientific advances with Hemostasis Today.